A Novel Peptide Enhances Therapeutic Efficacy of Liposomal Anti-Cancer Drugs in Mice Models of Human Lung Cancer
Author Information
Author(s): Chang De-Kuan, Lin Chin-Tarng, Wu Chien-Hsun, Wu Han-Chung
Primary Institution: Institute of Cellular and Organismic Biology, Academia Sinica, Taipei, Taiwan
Hypothesis
Can a novel peptide ligand improve the specificity and efficacy of chemotherapy for non-small cell lung cancer (NSCLC)?
Conclusion
The study found that the novel peptide significantly increased the therapeutic efficacy of liposomal doxorubicin and vinorelbine in mice with human lung cancer xenografts.
Supporting Evidence
- The targeting peptide increased drug accumulation in tumor tissues by 5.7-fold compared to free drugs.
- 75% of surgical specimens from lung cancer patients expressed a target molecule recognized by the peptide.
- Mice treated with the peptide-conjugated liposomes had significantly smaller tumors than those treated with non-targeted formulations.
- Survival rates of mice treated with the peptide were significantly higher than those treated with control therapies.
Takeaway
Researchers found a special peptide that helps cancer drugs work better by making them target only the cancer cells, which helps the medicine do its job without hurting normal cells.
Methodology
The study used a phage-displayed peptide library to isolate a peptide that binds specifically to NSCLC cells, and tested its efficacy in SCID mice with lung cancer xenografts.
Limitations
The study was conducted in mice, and further research is needed to confirm the findings in humans.
Participant Demographics
The study involved SCID mice bearing human lung cancer xenografts.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website